[Attempts at resuscitation in an acute clinic].
Explore the source record for details and available documents.
Adult↗
Biomedical subjects
L Erhardt
Publications and source records attributed to L Erhardt.
Osteolytic sterol in human breast cancer.
Eleven of twelve human breast cancers contained a lipid which increased urinary (45)Ca and (40)Ca excretion of (45)Ca-labeled, parathyroidectomized rats receiving a low Ca diet. The lipid has mobility on thin-layer chromatography and gas-liquid chromatography close to, but not identical with, that of 7-dehydrocholesterol. Authentic 7-dehydrocholesterol has osteolytic activity similar to that of the extracted sterol. Fluorescence and Lieberman-Burchard reactions of the extracted sterol are similar to those of 7-dehydrocholesterol. The lipid was found by thin-layer chromatography in the extracts which had osteolytic activity. Neither the lipid nor osteolytic activity was found in extracts of tissue from two normal human breasts.
Animals↗
Hemodynamic effects of ICI 118.587 (Corwin) in patients with mild cardiac failure after myocardial infarction.
The aim of this study was to compare the effects of intravenous ICI 118.587 (Corwin), a new cardioselective partial beta-agonist, and placebo given q. 12 h for 4 consecutive days, with invasive and noninvasive methods. Twelve patients with mild to moderate cardiac failure after a myocardial infarction were studied. We could not show any significant effect of Corwin on hemodynamics, systolic time intervals, heart rates, or blood pressures. We conclude that Corwin does not affect left ventricular function, as measured by hemodynamics and systolic time intervals, in the immediate postinfarction period in patients with mild to moderate heart failure.
Adrenergic beta-Agonists↗
Anticoagulant effects of low-molecular-weight heparin following thrombolytic therapy in acute myocardial infarction: a dose-finding study.
The aim of the present study was to gain clinical experience with different dose levels of dalteparin, a low-molecular-weight heparin, following thrombolytic therapy in acute myocardial infarction. Compared to heparin, dalteparin has a longer half-life and a greater and highly predictable bioavailability, which would suggest dalteparin to be a convenient alternative. Twenty patients with ECG signs of acute transmural myocardial ischemia received streptokinase (1.5 million IU for 60 min) and were allocated to a control group or to open treatment with 50, 75 or 100 IU of dalteparin/kg b.w. s.c. b.i.d., starting 4 h later, for 6 days. Each group consisted of 5 patients. Except for the control group, aspirin was withheld during dalteparin treatment. Anti-factor-Xa (anti-FXa) values increased dose-dependently during the first 24 h and were maintained throughout the study period. On day 6, anti-FXa levels after 100 IU/kg b.w. were 0.79 (0.59-1.00) IU/ml (median, min.-max.) 4 h after administration of dalteparin, and 0.51 (0.34-0.82) IU/ml before the subsequent dose of dalteparin. In conclusion, our results indicate that a dalteparin dose slightly higher than 100 IU/kg b.w. is required in order to obtain the presumed therapeutic range of anti-FXa (0.6-1.0 IU/ml).
Adult↗